Propanc Biopharma Highlights Therapeutic Potential of PRP

Propanc Biopharma (OTCQB:PPCB) shared the results of recent scientific experiments showing PRP with a potential effectiveness of a clinical approach for cancer patients.
As quoted in the press release:

The conclusion comes from observing the dramatic reduction of Epithelial to Mesenchymal Transition (EMT) markers as a consequence of PRP treatment, which not only reverses the EMT process, thereby stopping tumor progression and metastasis, but also represses the development of Cancer Stem Cells (CSCs).
The EMT is a process by which the characteristics of a cell become altered, where epithelial cells (from a normal functioning organ) adopt characteristics of mesenchymal cells (from lymphatic and circulatory systems, as well as bone or connective tissue), which enables them to migrate, invade surrounding tissues and survive longer. It is usually a normal biological process during embryogenesis and wound healing, but is also involved with tumor metastasis, chemo-resistance and spreading of CSCs, and is known to interact with other pathways central to cancer progression. Pathways which play an especially important role in aggressive tumors, like pancreatic cancer.

Click here to read the full press release.

Source: www.marketwired.com